GSK’s Malaria Drug Tafenoquine Heads To US FDA Panel Review With Agency Backing

 
• By Sue Sutter

Approval could bring GlaxoSmithKline a tropical disease priority review voucher.

Malaria Cells_321361517_1200.jpg
US FDA advisors will consider whether there is substantial evidence of effectiveness for tafenoquine as a radical cure for Plasmodium vivax malaria.

More from US FDA Performance Tracker

More from Regulatory Trackers